Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.

ABSTRACT:

Introduction

Rituximab has become the first-line therapy for patients with membranous nephropathy (MN). However, approximately 30-40% of patients with MN do not respond to rituximab. We presented our single-center experience of treating rituximab-refractory MN with obinutuzumab which is a humanized and glycoengineered type II anti-CD20 monoclonal antibody.

Methods

Seventeen patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated MN who received obinutuzumab at the First Affiliated Hospital of Xi'an Jiaotong University were included in this case series study. Clinical and laboratory parameters were evaluated at presentation, before and after obinutuzumab administration.

Results

Of all patients with an average age of 49.7 ± 13.7 years, 11 (64.7%)

SUBMITTER: Li H 

PROVIDER: S-EPMC12176347 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature